Victrex (VCT) H2 2025 earnings summary

Executive summary

• FY 2025 saw 12% volume growth but only a 1% revenue increase, with strong cash conversion and profit before tax down 21% due to currency headwinds, weaker medical spine, and China start-up costs.

• A profit improvement plan targeting at least £10m in savings was announced, leveraging infrastructure and digital investments, with full-year benefits expected in FY27.

• Cash conversion remained robust at 121%, aided by inventory reduction and lower CapEx.

• Updated capital allocation policy maintains dividends and targets net debt/EBITDA in the 0.5x–1.0x range.

Financial highlights

• Sales volume reached 4,164 tonnes, up 12% year-over-year, with revenue up 1% to £292.7m (3% in constant currency).

• Underlying PBT was £46.4m (down 21%), with FX impact of £8m and China start-up loss of £8m.

• Gross margin declined 90bps to 45.3% (47.7% ex-China plant impact).

• Free cash flow was £49.3m, with operating cash conversion at 121%.

• Dividend per share maintained at 59.56p.

Outlook and guidance

• FY 2026 targets low to mid-single digit volume growth, stable ASP, and gross margin in the 45.5%–46.5% range.

• Medical spine remains weak, but non-spine and sustainable solutions are expected to grow.

• Profit improvement plan to deliver most benefits in FY 2027, with some early gains in H2 2026.

• Guidance anticipates second-half weighting due to seasonality and currency headwinds in H1.

• Capex to remain at the lower end of 8–10% of revenue, with further working capital opportunities.